Browse Branding Content

Good science, and new customer behavior mean the time is right for companies to evaluate their portfolios to position themselves for success. Tailwinds are good, private equity interest is high, and the self-care future is bright.

Mar 13, 2023

Today we're going to be taking an in-depth look at the cosmetics and personal care industry in the context of corporate social responsibility. What is that industry doing to be environmentally sustainable and increase diversity in its companies, customer base, and images of beauty?

Jul 7, 2022

Advancing the beauty of diversity through multicultural marketing starts with connecting with consumers. These industry leaders discuss how it’s done.

Aug 2, 2021

In keeping with the mission of the FDA Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology Division of Medication Error and Prevention Analysis, this CHPA member feedback is designed to minimize the risk of medication errors due to consumer confusion attributed to an OTC drug product name.

Jun 14, 2021

In principle, CHPA supports an early approval program for proposed proprietary drug names. However, should FDA decide to implement a program, we expect that FDA would publish a draft Guidance for Industry and we would provide further comment based on the criteria.

Oct 27, 2014

CHPA appreciates the opportunity to provide comments on the FDA’s draft guidance for industry entitled “Best Practices in Developing Proprietary Names for Drugs”. CHPA members hope the Agency will find the suggested revisions in these comments informative as the final version of the guidance is developed.

Sep 15, 2014

These comments are submitted in response to the public meeting held June 5 and 6, 2008, on evaluating proposed proprietary names for drug products.

Jul 7, 2008

Letter to Daniel E. Troy, Esq. regarding whether there should be different trade-name evaluation procedures for different classes of drugs (Rx versus OTC).

Jul 9, 2003

These comments are submitted in response to the public meeting of June 26 on evaluating drug names for similarities, which was co-sponsored by the FDA, PhRMA, and the Institute for Safe Medication Practices.

Jul 9, 2003

Filter Results